BioSpace News Archive

The American Urological Association Board of Directors has unanimously approved the creation of the AUA Diversity and Inclusion Task Force, which aims to identify specific and actionable steps for how the AUA can advocate for, and foster, a diverse and inclusive environment within the association, as well as the global urology community.

World’s leading prostate cancer research non-profit encourages people to take simple science-based actions to raise awareness about how healthy lifestyles can help reduce cancer risk

Oncora Medical, an oncology data and software company, has been selected to power the Pediatric Proton/Photon Consortium Registry (PPCR), run out of the Mass General Cancer Center (MGCC), with their Oncora Analytics software platform. The PPCR is a consented registry for pediatric cancer patients with the

The first prospective, case-controlled clinical study of an Engineered Sharps Injury Prevention (ESIP) device to prevent Needle Stick Injuries (NSI) in an operating room demonstrated that the use of Operative Armour ® , a wearable needle safety and workflow efficiency device, reduces surgical needle passes and handling during surgi

Ridgeback Biotherapeutics LP (“Ridgeback”), a biotechnology company experienced in antiviral drug development, announced today that the U.S. Food and Drug Administration (“FDA”) approved Ebanga TM for the treatment of Ebola. Ebanga is now approved for treatment of infection caused by Zaire ebolavirus in adult and pediatric patients (including neonates

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the closing of its previously announced underwritten public offering of common stock, resulting in gross proceeds to the Company of $26.4 million.. The Company inte

MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the publication of a manuscript on MGD019, an investigational PD-1 × CTLA-4 bispecific DART molecule, in Cell Reports Medicine . MacroGenics’ DART platform allows for the creation of bispecific antibody-based molecules with the ability to bind t

If 2020 has taught us all anything, it is that consumers want easy access to accurate information to help them navigate these uneasy times.

BioEclipse Therapeutics™ (BioEclipse), a private clinical-stage biopharmaceutical company with a proprietary platform for developing next-generation cancer immunotherapies, today announced its President and CEO Pam Contag , Ph.D., will participate in Biotech Showcase Digital being held January 11-15, 2021 .

Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that its Investigational New Drug Application (IND) to study the use of CERC-007 to treat Still’s disease has been accepted by the United States Food and Drug Administration (FDA) and is now open. CERC-007 is a high affinity, fully human anti-